nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.05.2015 | Review – Clinical Oncology

Management of hepatocellular carcinoma

verfasst von: P. Fitzmorris, M. Shoreibah, B. S. Anand, A. K. Singal

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hepatocellular carcinoma (HCC), a common cause for cancer-related death, is increasing worldwide. Over the past decade, survival and quality of life of HCC patients have significantly improved due to better prevention strategies, early diagnosis, and improved treatment options. We performed this narrative review to synthesize current status on the HCC management.

Methods

Literature search for publications especially over the last decade, which has changed the paradigm on the management of HCC.

Results

Hepatitis B vaccination and treatment of chronic hepatitis B and C are important measures for HCC prevention. Screening and surveillance for HCC using ultrasonogram and alpha-fetoprotein estimation are directed toward cirrhotics and hepatitis B patients at high risk of HCC. If detected at an early stage, curative treatments for HCC can be used such as tumor resection, ablation and liver transplantation. HCC patients without curative options are managed by loco-regional therapies and systemic chemotherapy. Loco-regional treatments include trans-arterial chemoembolization, radioembolization and combinations of loco-regional plus systemic therapies. Currently, sorafenib is the only FDA-approved systemic therapy and newer better chemotherapeutic agents are being investigated. Palliative care for terminally ill patients with metastatic disease and/or poor functional status focusses on comfort care and symptom control.

Conclusions

In spite of significant advancement in HCC management, its incidence continues to rise. There remains an urgent need to continue refining understanding of HCC and develop strategies to increase utilization of the available preventive measures and curative treatment modalities for HCC.

Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K et al (1995) Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 108(3):768–775PubMedCrossRef

Adachi Y, Tsuchihashi J, Shiraishi N, Yasuda K, Etoh T, Kitano S (2003) AFP-producing gastric carcinoma: multivariate analysis of prognostic factors in 270 patients. Oncology 65(2):95–101PubMedCrossRef

Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G et al (2001) Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48(2):251–259PubMedCentralPubMedCrossRef

Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35(3):519–524PubMedCrossRef

Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC et al (1996) Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111(4):1018–1022PubMedCrossRef

Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430PubMedCrossRef

Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):S179–S188PubMedCrossRef

Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022PubMedCentralPubMedCrossRef

Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L (2013) Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer 49(16):3412–3419PubMedCrossRef

Castells A, Bruix J, Ayuso C, Bru C, Montanya X, Boix L et al (1995) Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol 22(4):410–415PubMedCrossRef

Cescon M, Cucchetti A, Grazi GL, Ferrero A, Vigano L, Ercolani G et al (2009) Indication of the extent of hepatectomy for hepatocellular carcinoma on cirrhosis by a simple algorithm based on preoperative variables. Arch Surg 144(1):57–63; discussion 63

Chen DS, Hsu NH, Sung JL, Hsu TC, Hsu ST, Kuo YT et al (1987) A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen—carrier mothers. JAMA 257(19):2597–2603PubMedCrossRef

Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ et al (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243(3):321–328PubMedCentralPubMedCrossRef

Cho YK, Kim JK, Kim MY, Rhim H, Han JK (2009) Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49(2):453–459PubMedCrossRef

Cholongitas E, Mamou C, Rodriguez-Castro KI, Burra P (2014) Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int. doi:10.1111/tri.12372

Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ et al (2002) High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 36(5):1221–1226PubMedCrossRef

Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A et al (2012) Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 13(1):e11–e22PubMedCentralPubMedCrossRef

Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D et al (2006) Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 101(3):513–523PubMedCrossRef

Cucchetti A, Cescon M, Bertuzzo V, Bigonzi E, Ercolani G, Morelli MC et al (2011) Can the dropout risk of candidates with hepatocellular carcinoma predict survival after liver transplantation? Am J Transplant 11(8):1696–1704PubMedCrossRef

Cucchetti A, Piscaglia F, Cescon M, Ercolani G, Terzi E, Bolondi L et al (2012) Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. Clin Cancer Res 18(16):4397–4405PubMedCrossRef

Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z et al (2011) Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 154(2):85–93PubMedCrossRef

Delis SG, Bakoyiannis A, Biliatis I, Athanassiou K, Tassopoulos N, Dervenis C (2009) Model for end-stage liver disease (MELD) score, as a prognostic factor for post-operative morbidity and mortality in cirrhotic patients, undergoing hepatectomy for hepatocellular carcinoma. HPB (Oxford) 11(4):351–357CrossRef

Diouf M, Filleron T, Barbare JC, Fin L, Picard C, Bouché O, Dahan L, Paoletti X, Bonnetain F (2013) The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol 2013(58):3

El-Serag HB (2001) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 5(1):87–107, vi

El-Serag HB (2002) Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35(5 Suppl 2):S72–S78PubMedCrossRef

El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127(5 Suppl 1):S27–S34PubMedCrossRef

El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365(12):1118–1127PubMedCrossRef

El-Serag HB, Davila JA (2011) Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol 4(1):5–10PubMedCentralPubMedCrossRef

Evan RJ, Kakati D, Shoreibah MG, Bloomer JR, Singal AK (2014) CT scans are overused for hepatocellular carcinoma screening in patients with cirrhosis. Gastroenterology 146(Suppl.), Abstract

Feng K, Yan J, Li X, Xia F, Ma K, Wang S et al (2012) A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 57(4):794–802PubMedCrossRef

Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR et al (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47(1):97–104PubMedCrossRef

Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379(9822):1245–1255PubMedCrossRef

Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K et al (2012) Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 265(1):115–123PubMedCentralPubMedCrossRef

Giorgio A, Tarantino L, de Stefano G, Coppola C, Ferraioli G (2005) Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a single center. AJR Am J Roentgenol 184(1):207–211PubMedCrossRef

Hama Y, Kusano S (2005) Liver abscess formation after hepatic chemoembolization for metastatic pancreatic neuroendocrine tumor. Minim Invasive Ther Allied Technol 14(1):6–7PubMedCrossRef

Hsu KY, Chau GY, Lui WY, Tsay SH, King KL, Wu CW (2009) Predicting morbidity and mortality after hepatic resection in patients with hepatocellular carcinoma: the role of Model for End-Stage Liver Disease score. World J Surg 33(11):2412–2419PubMedCrossRef

Huang SF, Ko CW, Chang CS, Chen GH (2003) Liver abscess formation after transarterial chemoembolization for malignant hepatic tumor. Hepatogastroenterology 50(52):1115–1118PubMed

Huang K, Zhou Q, Wang R, Cheng D, Ma Y (2014) Doxorubicin-eluting beads versus convention transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 25(5):920–925CrossRef

Huo TI, Lin HC, Hsia CY, Wu JC, Lee PC, Chi CW et al (2007) The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol 102(9):1920–1930PubMedCrossRef

Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S et al (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38(2):200–207PubMedCrossRef

Ioannou GN, Perkins JD, Carithers RL Jr (2008) Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 134(5):1342–1351PubMedCrossRef

Jepsen P, Vilstrup H, Tarone RE, Friis S, Sorensen HT (2007) Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. Int J Cancer 121(7):1624–1626PubMedCrossRef

Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H (2012) Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med 156(12):841–847, W295

Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL (2013) Brivanib versus sorafenib as first line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31(28):3517–3524PubMedCrossRef

Kojiro M (2004) Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view. Liver Transplant 10(2 Suppl 1):S3–S8CrossRef

Kudo M (2011) Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy. Oncology 81(Suppl 1):1–10PubMedCrossRef

Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, Yang J, Lu L, Tak WY, Yu X, Lee JH, Lin SM, Wu C, Tanwandee T, Shao G, Walters IB, Dela Cruz C, Poulart V, Wang JH (2014) Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase 3 trial. Hepatology. doi:10.1002/hep.27290

Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52PubMedCentralPubMedCrossRef

Lee JM, Yoon JH, Kim KW (2012) Diagnosis of hepatocellular carcinoma: newer radiological tools. Semin Oncol 39(4):399–409PubMedCrossRef

Levy I, Greig PD, Gallinger S, Langer B, Sherman M (2001) Resection of hepatocellular carcinoma without preoperative tumor biopsy. Ann Surg 234(2):206–209PubMedCentralPubMedCrossRef

Liang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y et al (2012) Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transplant 18(1):62–69CrossRef

Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H et al (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351(15):1521–1531PubMedCrossRef

Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB (2012) Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg 99(12):1622–1629PubMedCrossRef

Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C et al (2008) Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47(1):82–89PubMedCrossRef

Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429–442PubMedCrossRef

Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1):S20–S37PubMedCrossRef

Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30(6):1434–1440PubMedCrossRef

Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L et al (2000) Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31(1):54–58PubMedCrossRef

Llovet JM, Vilana R, Bru C, Bianchi L, Salmeron JM, Boix L et al (2001) Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 33(5):1124–1129PubMedCrossRef

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX et al (2008a) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100(10):698–711PubMedCrossRef

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008b) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390PubMedCrossRef

Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW (2013) Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31(28):3509–3516PubMedCrossRef

Maithel SK, Kneuertz PJ, Kooby DA, Scoggins CR, Weber SM, Martin RC, 2nd et al (2011) Importance of low preoperative platelet count in selecting patients for resection of hepatocellular carcinoma: a multi-institutional analysis. J Am Coll Surg 212(4), 638–648; discussion 648–650

Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J et al (1997) Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 226(6):688–701; discussion 701–683

Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S et al (2008) Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 31(2):269–280PubMedCrossRef

Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ (1995) Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 21(6):1535–1542PubMed

Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ et al (2003) Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 37(5):1114–1121PubMedCrossRef

Massie AB, Caffo B, Gentry SE, Hall EC, Axelrod DA, Lentine KL et al (2011) MELD exceptions and rates of waiting list outcomes. Am J Transplant 11(11):2362–2371PubMedCentralPubMedCrossRef

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693–699PubMedCrossRef

Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchianò A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, Spreafico C (2013) Ytrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 57(5):1826–1837PubMedCrossRef

Minagawa M, Makuuchi M, Takayama T, Kokudo N (2003) Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 238(5):703–710PubMedCentralPubMedCrossRef

Morimoto O, Nagano H, Sakon M, Fujiwara Y, Yamada T, Nakagawa H et al (2003) Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol 39(2):215–221PubMedCrossRef

Mueller GC, Hussain HK, Carlos RC, Nghiem HV, Francis IR (2003) Effectiveness of MR imaging in characterizing small hepatic lesions: routine versus expert interpretation. AJR Am J Roentgenol 180(3):673–680PubMedCrossRef

National Comprehensive Cancer Network Guidelines. www.nccn.org

Naimark D, Naglie G, Detsky AS (1994) The meaning of life expectancy: what is a clinically significant gain? J Gen Intern Med 9(12):702–707PubMedCrossRef

Nerenstone SR, Ihde DC, Friedman MA (1988) Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 15(1):1–31PubMedCrossRef

Nicolini D, Svegliati-Baroni G, Candelari R, Mincarelli C, Mandolesi A, Bearzi I et al (2013) Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol 19(34):5622–5632PubMedCentralPubMedCrossRef

Nowak AK, Stockler MR, Chow PK, Findlay M (2005) Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review. Cancer 103(7):1408–1414PubMedCrossRef

Okada S (1999) Local ablation therapy for hepatocellular carcinoma. Semin Liver Dis 19(3):323–328PubMedCrossRef

Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56(4):918–928PubMedCrossRef

Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M (2009) Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 104(2):514–524PubMedCrossRef

Park YN, Kojiro M, Di Tommaso L, Dhillon AP, Kondo F, Nakano M et al (2007) Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer 109(5):915–923PubMedCrossRef

Park CW, Tsai NT, Wong LL (2011) Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more. Clin Transplant 25(6):E606–E611PubMedCrossRef

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRef

Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB (2013) Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography—a randomised study. Aliment Pharmacol Ther 38(3):303–312PubMedCrossRef

Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M et al (2010) Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transplant 16(3):262–278CrossRef

Porta C, Paglino C (2010) Medical treatment of unresectable hepatocellular carcinoma: going beyond sorafenib. World J Hepatol 2(3):103–113PubMedCentralPubMed

Raoul JL, Guyader D, Bretagne JF, Duvauferrier R, Bourguet P, Bekhechi D et al (1994) Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 35(11):1782–1787PubMed

Robic MA, Procopet B, Metivier S, Peron JM, Selves J, Vinel JP et al (2011) Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol 55(5):1017–1024PubMedCrossRef

Saab S, Ly D, Nieto J, Kanwal F, Lu D, Raman S et al (2003) Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transplant 9(7):672–681CrossRef

Sala M, Fuster J, Llovet JM, Navasa M, Sole M, Varela M et al (2004) High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transplant 10(10):1294–1300CrossRef

Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L (2010) Radioembolization for hepatocellular carcinoma using Ytrium-90 microspheres: a comprehensive report of long-term outcomes. J Gastroenterol 138(1):52–64CrossRef

Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140(2):497–507 e492

Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, Baker T, Abecassis MM, Atassi R, Riaz A, Cella D, Burns JL, Ganger D, Benson AB 3rd, Mulcahy MF, Kulik L, Lewandowski R (2013) Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 11(10):1358–1365PubMedCrossRef

Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, Linari S et al (2003) A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 102(1):78–82PubMedCrossRef

Sarasin FP, Giostra E, Hadengue A (1996) Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 101(4):422–434PubMedCrossRef

Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A (2001) Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. Hepatology 33(5):1073–1079PubMedCrossRef

Sato H, Maruta M, Kuromizu J, Utumi T, Touyama K, Takizawa K (1994) AFP-producing intestinal cancer. Nihon Rinsho Suppl 6:7–10PubMed

Sato M, Tateishi R, Yasunaga H, Horiguchi H, Yoshida H, Matsuda S et al (2012) Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patients. J Gastroenterol 47(10):1125–1133PubMedCrossRef

Schnitzbauer AA (2010) A prospective randomized, open-labeled trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing. BMC Cancer 1(10):190CrossRef

Schwartz JD, Schwartz M, Mandeli J, Sung M (2002) Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 3(10):593–603PubMedCrossRef

Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A et al (2008) Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103(4):914–921PubMedCrossRef

Shen A, Tang C, Wang Y, Chen Y, Yan X, Zhang C et al (2013) A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma. J Clin Gastroenterol 47(10):871–880PubMedCrossRef

Shirabe K, Kanematsu T, Matsumata T, Adachi E, Akazawa K, Sugimachi K (1991) Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology 14(5):802–805PubMedCrossRef

Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF (2008) Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57(11):1592–1596PubMedCrossRef

Singal AK, Fontana RJ (2011) Oral antiviral agents reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B: systematic review and meta-analysis. Hepatology 54:1016A

Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA et al (2009) Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 30(1):37–47PubMedCrossRef

Singal AK, Freeman DH, Anand BS (2010a) Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 32(7):851–858PubMedCrossRef

Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF et al (2010b) Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 8(2):192–199PubMedCrossRef

Singal AG, Pillai A, Tiro J (2014) Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 11(4):e1001624PubMedCentralPubMedCrossRef

Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M et al (2005) Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg 9(9):1207–1215; discussion 1215

Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM (2010) Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 51(4):1237–1243PubMedCrossRef

Toso C, Dupuis-Lozeron E, Majno P, Berney T, Kneteman NM, Perneger T et al (2012) A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology 56(1):149–156PubMedCrossRef

Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P et al (2001) Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34(4):570–575PubMedCrossRef

Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnu L, Zoli M et al (2002) Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 97(3):734–744PubMedCrossRef

Trotter JF, Wachs M, Everson GT, Kam I (2002) Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 346(14):1074–1082PubMedCrossRef

Ulahannan SV, Duffy AG, McNeel TS, Kish JK, Dickie LA, Rahma OE et al (2014) Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology. doi:10.1002/hep.27288

Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46(3):474–481PubMedCrossRef

Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N et al (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20(6):1527–1536PubMedCrossRef

Washburn K, Edwards E, Harper A, Freeman R (2010) Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 10(7):1643–1648PubMedCrossRef

Welch J, Shukla R, Igbo NL, Singal AK, Kazan-Tannus JF, Soloway RD (2010) Use of ultrasound as initial imaging exam for hepatocellular carcinoma in high risk populations. Gastroenterology (Suppl.):S219

Wiesner RH, Freeman RB, Mulligan DC (2004) Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 127(5 Suppl 1):S261–S267PubMedCrossRef

Winslow E, Hawkins WG (2013) Laparoscopic resection of the liver for cancer. Surg Oncol Clin N Am 22(1):75–89PubMedCrossRef

Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS et al (2012) Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308(18):1906–1914PubMedCrossRef

Xu G, Qi FZ, Zhang JH, Cheng GF, Cai Y, Miao Y (2012) Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. World J Surg Oncol 10:163PubMedCentralPubMedCrossRef

Yamasaki S, Hasegawa H, Kinoshita H, Furukawa M, Imaoka S, Takasaki K et al (1996) A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 87(2):206–211PubMedCrossRef

Yan S, Xu D, Sun B (2012) Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci 57(11):3026–3031PubMedCrossRef

Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V et al (2002) Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transplant 8(10):873–883CrossRef

Zhang BH, Yang BH, Tang ZY (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130(7):417–422PubMedCrossRef

Zhang L, Hu P, Chen X, Bie P (2014) Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS One 9(6):e100305

Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J et al (2008) Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 143(2):182–188; discussion 188PubMedCrossRef

Titel: Management of hepatocellular carcinoma
verfasst von: P. Fitzmorris
M. Shoreibah
B. S. Anand
A. K. Singal
Publikationsdatum: 01.05.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1806-0

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Springer Medizin

Management of hepatocellular carcinoma

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Genetic polymorphisms of phase I and phase II metabolic enzymes as modulators of lung cancer susceptibility

The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients

Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation

Measurement of genome-wide DNA methylation predicts survival benefits from chemotherapy in non-small cell lung cancer

Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie